​***If you're a T2B member and do not receive your confirmation within 1 business day of RSVPing (above), check your email spam folder. The automated Luma email includes the cal invite.***

​T2Bmeet pricing:

• ​Complimentary for T2B Pro and Student community members (log into your T2B account and access your promo code here)

• ​$50 for Basic members

​If you're not part of Ticket to Biotech, confirm you're eligible, and join before registering for this event:

​T2B Intake Form

​Join us for our first in-person meetup in Boston of 2026! In addition to the casual networking that T2B events are known for, we're kicking off the new year with a panel discussion. Open to all biopharma communicators in the T2B community.

​Program:

• ​4:30-5:30 p.m. - Check-in and networking

• ​5:30-6:15 p.m. - Panel discussion and Q&A

• ​6:15-7 p.m. - Reception and networking

​Complimentary snacks and drinks will be provided. ​See you there!

​Communications Career Choices That Compound

​Career growth in biopharma communications requires strategic choices beyond technical excellence. We're experienced professionals navigating cross-functional partnerships, developing well-rounded capabilities, and leading teams through continuous organizational change. The challenge comes when there's limited guidance on critical decisions: when to broaden versus deepen expertise, how to stay essential through volatility, and how to build influence that survives restructuring and market shifts. This panel examines the career strategy decisions and leadership development approaches that position communications professionals as indispensable strategic partners, not just skilled practitioners.

​Takeaways:

• ​Develop comprehensive capabilities across communications disciplines through intentional choices about when to specialize deeply versus when to expand your strategic range

• ​Examine how cross-functional business fluency earns you strategic partnership in C-suite decisions beyond communications execution

• ​Lead teams effectively through organizational volatility when budget pressures and restructuring create constant workforce fluctuations

• ​Explore how ongoing mentorship practices—including peer and reverse mentoring—keep senior leaders adaptable in rapidly evolving industry and communications landscapes

​Meet Our Speakers

​Paul Cox, VP, IR and Corporate Communications, Dynavax

​Paul Cox is Vice President, Investor Relations and Corporate Communications at Dynavax, a commercial-stage vaccines company. Mr. Cox has 20 years of experience leading IR and communications in the biopharma and technology industries. Before joining Dynavax, he held leadership roles in investor relations, communications and corporate strategy at biotechnology companies including Neumora Therapeutics, Kymera Therapeutics, Sage Therapeutics, Voyager Therapeutics, Neon Therapeutics (acquired by BioNTech), as well as at multiple strategic consulting firms, including Stern IR. He has been ranked in Institutional Investor’s All-America Executive Team in multiple investor relations categories and previously served as President of the National Investor Relations Institute (NIRI) Boston chapter. He holds a B.A. in Political Science from the University of Massachusetts Amherst and a Master’s degree in Finance from Harvard University Extension School.

​Nina Devlin, SVP and Chief Communications Officer, Vertex

​Nina Devlin joined Vertex in 2019 as Senior Vice President and Chief Communications Officer. In this role, she is responsible for leading the global corporate communications function, spanning product communications, media relations, digital and social communications, internal communications, and corporate reputation.

​Ms. Devlin joined Vertex from the U.S. Food and Drug Administration (FDA), where she served as senior communications advisor to FDA Commissioner Scott Gottlieb. Prior to this, Ms. Devlin spent seven years as the Head of Global Communications for Mylan NV (now known as Viatris), one of the world’s largest generics and specialty pharmaceutical companies, overseeing external, financial, digital and internal communications, as well as the company’s corporate social responsibility program. Before Mylan, Ms. Devlin spent 15 years at leading global communications agencies, including Edelman and Brunswick Group, working predominantly on issues and crisis management.

​Ms. Devlin received her bachelor’s degree in international relations from Georgetown University’s School of Foreign Service. 

​Darcie Robinson, SVP, Supreme Communications

​Darcie Robinson is a senior vice president at Supreme Communications, a full-service PR and communications agency dedicated to healthcare and life sciences brands. With nearly 15 years of experience in life science communications, Darcie has counseled a wide range of companies through defining moments — critical inflection points, transformative milestones, and periods of significant organizational change. As a trusted advisor to clients and C-suite leaders, she brings deep strategic and cross-functional partnership that elevates communications from a tactical function to a core business driver.

Prior to Supreme Communications, Darcie spent more than six years building the healthcare and life sciences PR practice at ICR Westwicke. She also held roles at Chamberlain Healthcare PR (part of Syneos Health) and Boehringer Ingelheim. Darcie has a bachelor’s degree in communications from St. Lawrence University and a master’s degree in mass communications from Iona College.

​

​About Our Host, Vertex

​Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

​Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex’s history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.